Cellnovo presents its unique mobile diabetes management system at Nordic Mobile Health Technology Congress

Regulatory News:

Cellnovo Group (Paris:CLNV) ("Cellnovo” CLNV:EN Paris), a medical technology company marketing the first connected all-in-one diabetes management system, today announced that Dr. Julian Shapley, Chief Scientific Officer and inventor of Cellnovo’s unique pump technology, presented Cellnovo’s mobile diabetes management system at the Nordic Mobile Health Technology Congress in Stockholm on November 11^th and 12^th.

The Nordic Mobile Health Technology Congress gathers leaders and policy makers from the health industry sector and healthcare institutions to share their experiences and to gain practical guidance on integrating the latest technologies into health and social care.

This meeting provided a great opportunity for Cellnovo to take part in a consortium to address some of the key challenges with regard to Mobile Healthcare Technology. The Nordic region is known for being a pioneer in the adoption of new technologies and this congress was the opportunity to demonstrate the benefits for this arena ahead of the Cellnovo system’s launch in Scandinavia planned for early 2016.

Cellnovo’s unique solution represents a major breakthrough in the way diabetes is treated. This technology empowers patients by combining a high-tech insulin micro-pump with the convenience of a mobile system that includes real-time data transmission. Access to the data allows patients and clinicians to make more informed decisions with the confidence of accurate and comprehensive knowledge of the patient’s personal needs.

Dr. Julian Shapley, Chief Scientific Officer of Cellnovo, commented: "We were delighted to present our innovative technology to thought leaders and industry experts in e-health and mobile health systems. Cellnovo’s insulin pump is discreet, compact, silent, tubeless, entirely connected and has intuitive features. It has the potential to transform the way people with diabetes manage their lives.”

Sophie Baratte, CEO of Cellnovo, concluded: "Taking part in this meeting was important as it enabled us to showcase and promote our solution before the launch of our diabetes management system within the Nordic region, planned for early 2016, as well as to re-iterate our leadership position in mobile health in diabetes technologies. We look forward to the launch in Scandinavia and others to expand our commercial network in new countries over the coming months.”

About Cellnovo

An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first connected all-in-one diabetes management system that helps make life easier for patients. Compact, tubeless, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real-time.

For further information please visit www.cellnovo.com

Cellnovo is listed on Euronext, Compartment C
ISIN: FR0012633360 – Ticker: CLNV

View source version on businesswire.com: http://www.businesswire.com/news/home/20151115005029/en/